Current role
Drug Manufacturers - Specialty & Generic · Healthcare
Board Member
Marco Taglietti
Board Member
Aquestive Therapeutics, Inc. (AQST)Equibles does not estimate personal net worth.
Get an email with a short summary when Aquestive Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get AQST alertsAbout Marco Taglietti
Marco Taglietti is recorded as Board Member at Aquestive Therapeutics, Inc. (AQST). The newest filing on record that lists Marco Taglietti as Board Member at Aquestive Therapeutics, Inc. (AQST) is dated April 24, 2026. Earlier roles on record: CEO and Board Member at Scynexis Inc (SCYX) until December 31, 2022. Scynexis Inc reported in an 8-K filed October 20, 2022 that Marco Taglietti retired as Board of Directors, effective December 31, 2022. Scynexis Inc reported in an 8-K filed October 20, 2022 that Marco Taglietti retired as President and Chief Executive Officer, effective December 31, 2022. The proxy statement of Scynexis Inc reports total compensation of $2,608,785 for Marco Taglietti in fiscal 2022, including a base salary of $598,637. Disclosed compensation is on record for 5 fiscal years. Marco Taglietti has spoken on 5 earnings calls across 1 company, most recently for Scynexis Inc on November 9, 2022. Aquestive Therapeutics, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other companies whose calls Marco Taglietti spoke on are classified in the Healthcare sector. Other leadership on record at Aquestive Therapeutics, Inc. includes Daniel Barber (CEO and Board Member), Gregory B. Brown (Chairman), John S. Cochran (Chairman) and 7 others.
“On October 14, 2022, Dr. Marco Taglietti announced to SCYNEXIS, Inc. that he plans to retire and will leave his position as President and Chief Executive Officer of SCYNEXIS, and will step down from the SCYNEXIS Board of Directors, on December 31, 2022.”
“On October 14, 2022, Dr. Marco Taglietti announced to SCYNEXIS, Inc. that he plans to retire and will leave his position as President and Chief Executive Officer of SCYNEXIS, and will step down from the SCYNEXIS Board of Directors, on December 31, 2022.”
Marco Taglietti on recent calls
“I want to begin by drawing your attention to a recent report issued by the World Health Organization or WHO. This was the first ever list of priority deadly fungal pathogens that are becoming a growing global public health concern.”
“Things are moving forward nicely here at SCYNEXIS. We are now one of the leading standalone anti-infective companies, a sector marked by unpredictability and utmost urgency.”
“We are excited to share with you updates on the progress of the launch of BREXAFEMME and to outline our vision for the future of the ibrexafungerp franchise. 2022 is a pivotal year for SCYNEXIS and we are making great strides.”
“Good morning, everyone, and thank you for joining us today for our fourth quarter and full year 2021 earnings investor call. We are excited to share with you updates on the progress of the launch of BREXAFEMME and outline our vision for the future of the ibrexafungerp franchise.”
“Good morning, everyone, and thank you for joining us today for our third quarter 2021 earnings investor call. This is our inaugural earnings call with investors since the FDA approval in June and after the launch of BREXAFEMME.”
Affiliation history
-
Current
Start not stated–present
Last confirmed April 24, 2026
-
Start not stated–2022-12-31
-
Start not stated–2022-12-31
Company network
Scynexis Inc
SCYX
Drug Manufacturers - Specialty & Generic · Healthcare
CEO, Board Member
5 appearances
Latest appearance 2022-11-09
View calls and events
Leadership on record at Aquestive Therapeutics, Inc.
- Daniel Barber CEO, Board Member
- Gregory B. Brown Chairman
- John S. Cochran Chairman
- A. Ernest Toth CFO
- A. Ernest Toth, Jr. CFO
- Cassie Jung COO
- Thomas A. Zalewski General Counsel
- Abigail L. Jenkins Board Member
- Julie Krop Board Member
- Richard J. Daly Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Scynexis Inc (SCYX) | Former President and Chief Executive Officer | $598,637 | $2,608,785 |
| 2021 | Scynexis Inc (SCYX) | Former President and Chief Executive Officer | $569,545 | $1,714,217 |
| 2020 | Scynexis Inc (SCYX) | President and Chief Executive Officer | $552,970 | $1,449,548 |
| 2019 | Scynexis Inc (SCYX) | President and Chief Executive Officer | $542,500 | $1,534,585 |
| 2018 | Scynexis Inc (SCYX) | President and Chief Executive Officer | $526,666 | $1,114,895 |